GENITOURINARY CANCERS ASCO Poster review
|
|
- Rosamund Williams
- 5 years ago
- Views:
Transcription
1 GENITOURINARY CANCERS ASCO Poster review Francesco Massari Oncologia Medica Azienda Ospedaliero Universitaria di Bologna Policlinico S. Orsola-Malpighi AIOM POST-ASCO REVIEW: Updates and news from the Annual Meeting in Chicago - Milano,
2 Disclosures No pertinent C.O.I. with this presentation Advisory Boards/Honoraria/Consultant for: Astellas BMS Janssen Merk Pfizer Roche
3 Prostate: 92 Kidney: 48 Urothelial: 37 Testis : 10 Penis: 1 GENITOURINARY 188 Poster
4 Urothelial Cancer
5 Novel therapeutic strategies for advanced bladder cancer Abstract #4512: BMS , an indoleamine 2,3-dioxygenase 1 inhibitor (IDO1i), in combination with nivolumab (NIVO): Updated safety across all tumor cohorts and efficacy in pts with advanced bladder cancer (advbc). Abstract #4513: Rogaratinib in patients with advanced urothelial carcinomas prescreened for tumor FGFR mrna expression and effects of mutations in the FGFR signaling pathway. Tabernero J et al., J Clin Oncol 36, 2018 (suppl; abstr 4512) Joerger M et al., J Clin Oncol 36, 2018 (suppl; abstr 4513)
6 Novel therapeutic strategies for advanced bladder cancer Abstract #4512: BMS , an indoleamine 2,3-dioxygenase 1 inhibitor (IDO1i), in combination with nivolumab (NIVO): Updated safety across all tumor cohorts and efficacy in pts with advanced bladder cancer (advbc). Abstract #4513: Rogaratinib in patients with advanced urothelial carcinomas prescreened for tumor FGFR mrna expression and effects of mutations in the FGFR signaling pathway. Tabernero J et al., J Clin Oncol 36, 2018 (suppl; abstr 4512) Joerger M et al., J Clin Oncol 36, 2018 (suppl; abstr 4513)
7 Study Design Phase 1/2a, open label, dose escalation, cohort-expansion Safety, tolerability, efficacy of BMS alone or combined with NIVO in advanced cancer Dose escalation methods previously described Expansion: BMS mg or 200 mg QD + NIVO 240 mg Q2W or 480 Q4W Advanced bladder cancer: 100 or 200 mg QD + NIVO 240 mg Q2W Tabernero J et al., J Clin Oncol 36, 2018 (suppl; abstr 4512)
8 Baseline characteristics in all Patients Tabernero J et al., J Clin Oncol 36, 2018 (suppl; abstr 4512)
9 Bladder cancer expansion cohort Safety Tabernero J et al., J Clin Oncol 36, 2018 (suppl; abstr 4512)
10 Bladder cancer expansion cohort Activity Tabernero J et al., J Clin Oncol 36, 2018 (suppl; abstr 4512)
11 BMS Nivolumab Open questions Is this practice changing routine day-to-day practice right now? NO Strengths: robust mechanistic rationale, very well designed/conducted, phase II dose identified (100 mg) Weakness: small sample size
12 Novel therapeutic strategies for advanced bladder cancer Abstract #4512: BMS , an indoleamine 2,3-dioxygenase 1 inhibitor (IDO1i), in combination with nivolumab (NIVO): Updated safety across all tumor cohorts and efficacy in pts with advanced bladder cancer (advbc). Abstract #4513: Rogaratinib in patients with advanced urothelial carcinomas prescreened for tumor FGFR mrna expression and effects of mutations in the FGFR signaling pathway. Tabernero J et al., J Clin Oncol 36, 2018 (suppl; abstr 4512) Joerger M et al., J Clin Oncol 36, 2018 (suppl; abstr 4513)
13 Fibroblast Growth Factor Receptor (FGFR) Pathway Activating mutations common (80-85%) in low grade and early stage bladder tumors FGFR3 mutations/fusions (20% in advanced UC) more common in high grade invasive tumors and upper tract UC Putative driving role in tumorigenesis and chemotherapy/immunotherapy resistance Pharmacologic inhibition has cytostatic effect with G0 or G1 arrest. Massari F et al. Expert Rev Anticancer Ther Nov 14:1-3
14 Prevalence of FGFR1-3 mrna overexpression and FGFR3 gene mutations Phase 1 expansion cohort of late-stage muscle invasive UC FFPE tumor tissue FGFR1-3 mrna overexpression screened by RNA ISH and by NanoString ncounter FGFR1-3 mrna positive patients treated with ROGARATINIB 800 mg BID (continuous 21-day cycle) Joerger M et al., J Clin Oncol 36, 2018 (suppl; abstr 4513)
15 Rogaratinib Efficacy ORR 24% (1 CR, 11 PR); 49% SD; DCR 73% No Patient with response had mutations in either PIK3CA or RAS-encoding genes, but 7 of 14 patients with PD had mutations in either genes UC patients with wilde-type PIK3CA/RAS ORR 33% 7/11 responders showed FGFR3 mrna overexpression without FGFR3 gene mutations/translocation Joerger M et al., J Clin Oncol 36, 2018 (suppl; abstr 4513)
16 Rogaratinib Toxicity Joerger M et al., J Clin Oncol 36, 2018 (suppl; abstr 4513)
17 Rogaratinib : What did we learn? Treatment with Rogaratinib demonstrated clinical benefit in UC tumors with FGFR3 mrna overexpression but without FGFR3 gene mutation The use of mrna-based screening identified additional rogaratinib-sensitive patients with UC with FGFR1 mrna overexpression Rogaratinib treatment in patients with advance UC with FGFR overexpression resulted in a manageable safety profile and encouraging efficacy, including in patients refractory to prior immuno-oncology treatment, but not in those harbouring PIK3CA or RAS mutations Joerger M et al., J Clin Oncol 36, 2018 (suppl; abstr 4513)
18 Prostate Cancer
19 Prostate cancer poster Abstract #LBA5009: Abi Race: A prospective, multicenter study of black (B) and white (W) patients (pts) with metastatic castrate resistant prostate cancer (mcrpc) treated with abiraterone acetate and prednisone (AAP). Abstract #5015: Phase 2 randomized cross-over trial of abiraterone + prednisone (ABI+P) vs enzalutamide (ENZ) for patients (pts) with metastatic castration resistant prostate cancer (mcprc): Results for 2ndline therapy. George DJ et al., J Clin Oncol 36, 2018 (suppl; abstr LBA5009) Khalaf D et al., J Clin Oncol 36, 2018 (suppl; abstr 5015)
20 Prostate cancer poster Abstract #LBA5009: Abi Race: A prospective, multicenter study of black (B) and white (W) patients (pts) with metastatic castrate resistant prostate cancer (mcrpc) treated with abiraterone acetate and prednisone (AAP). Abstract #5015: Phase 2 randomized cross-over trial of abiraterone + prednisone (ABI+P) vs enzalutamide (ENZ) for patients (pts) with metastatic castration resistant prostate cancer (mcprc): Results for 2ndline therapy. George DJ et al., J Clin Oncol 36, 2018 (suppl; abstr LBA5009) Khalaf D et al., J Clin Oncol 36, 2018 (suppl; abstr 5015)
21 Abi Race: mcrpc outcomes by race Black men have 2.5 times likelihood of dying from prostate cancer but are underrepresented in clinical trials 2-5% of recent mcrpc RCT patients were black Subgroup analyses impossible by race due to low numbers COU-302 data suggest possible higher PSA 90 rates and longer median rpfs for black man Side effect profiles may different by race George DJ et al., J Clin Oncol 36, 2018 (suppl; abstr LBA5009)
22 Abi Race: mcrpc outcomes by race Do prostate cancer specific and side effect outcomes differ by race during treatment with abiraterone? Is it feasible to enroll a prostate cancer clinical trial including 50% black men?
23 Abi Race Trial Design Non-comparative pilot open-label, parallel arm study of AP in 100 men (50 B, 50 W) with mcrcpc, self-identified race George DJ et al., J Clin Oncol 36, 2018 (suppl; abstr LBA5009)
24 Abi Race Radiographic Progression Free Survival rpfs Similar by Race George DJ et al., J Clin Oncol 36, 2018 (suppl; abstr LBA5009)
25 Abi Race PSA-Progression Free Survival Longer PSA PFS by Race George DJ et al., J Clin Oncol 36, 2018 (suppl; abstr LBA5009)
26 Abi Race Toxicity Profile (any grade) George DJ et al., J Clin Oncol 36, 2018 (suppl; abstr LBA5009)
27 Abi Race Different Genotypic Clusters (SNP Analysis) George DJ et al., J Clin Oncol 36, 2018 (suppl; abstr LBA5009)
28 Abi Race: What did we learn? Inclusion of representative number of black men in mcrpc clinical trials is feasible PSA response may differ by race during treatment with abiraterone despite similar rpfs Further studies including more patients are required to confirm it. Adverse events rates may vary by race Could germline SNP differences in androgen transport genes and others be driving differences in outcomes and toxicity profiles? George DJ et al., J Clin Oncol 36, 2018 (suppl; abstr LBA5009)
29 Prostate cancer poster Abstract #LBA5009: Abi Race: A prospective, multicenter study of black (B) and white (W) patients (pts) with metastatic castrate resistant prostate cancer (mcrpc) treated with abiraterone acetate and prednisone (AAP). Abstract #5015: Phase 2 randomized cross-over trial of abiraterone + prednisone (ABI+P) vs enzalutamide (ENZ) for patients (pts) with metastatic castration resistant prostate cancer (mcprc): Results for 2ndline therapy. George DJ et al., J Clin Oncol 36, 2018 (suppl; abstr LBA5009) Khalaf D et al., J Clin Oncol 36, 2018 (suppl; abstr 5015)
30 Phase II Study design Khalaf D et al., J Clin Oncol 36, 2018 (suppl; abstr 5015)
31 Best PSA decline at 12 weeks for 2 nd line therapy Khalaf D et al., J Clin Oncol 36, 2018 (suppl; abstr 5015)
32 Outcomes on 2 nd line therapy Psa response rate and time to progression were better for second-line enzalutamide compared to abiraterone plus prednisone Khalaf D et al., J Clin Oncol 36, 2018 (suppl; abstr 5015)
33 Treatment Outcomes from start of 1 st line therapy Khalaf D et al., J Clin Oncol 36, 2018 (suppl; abstr 5015)
34 Proportion of ctdna at baseline and outcome Presence of ctdna is associated with worse outcomes on Abi+P and Enza Khalaf D et al., J Clin Oncol 36, 2018 (suppl; abstr 5015)
35 Genomic alterations on baseline ctdna predict outcome Worse outcomes BRCA2/ATM truncating mutation TP53 defects AR amplification (new AR mutations were detected at crossover or progression) Better outcomes SPOP mutations Khalaf D et al., J Clin Oncol 36, 2018 (suppl; abstr 5015)
36 Abi+P vs. Enza cross-over trial: What did we learn? The optimal sequencing of Abi+P and Enza remains unknown No difference in OS Larger studies with longer follow up are needed ctdna as a liquid biopsy approach Risk stratification/prognostication Treatment selection Monitoring treatment response
37 Kidney Cancer
38 Novel Combinations for Advanced Renal Cell Carcinoma Doublet Nivolumab-Ipilimumab will be SOC in intermediate/poor risk mrcc
39 Phase 3 Nivolumab + Ipilimumab Escudier B et al. ESMO 2017; Abstract LBA5
40 CheckMate 214 Results Escudier B et al. ESMO 2017; Abstract LBA5
41 CheckMate 214 Results Escudier B et al. ESMO 2017; Abstract LBA5
42 Novel Combinations for Advanced Renal Cell Carcinoma Doublet Nivolumab-Ipilimumab will be SOC in intermediate/poor risk mrcc Furthermore, IO-VEGF combination trials may add in the first line treatment approach in all risk group or biomarker based population However, either upfront or secondary acquired resistance raise the question of alternative or rescue treatment Therefore, there is a need for new strategy development New targets identification Which backbone in case of combination: PD-1? VEGF?
43 PD-1 blockade.in combination with? Anti PD-L1 MEDI4736 DC vaccines Anti LAG3 BMS Tyrosin kinase inhibitors PD-1 blockade Anti-CTLA-4 Ipilimumab IDO1 inhibitors 41BB agonist monoclonal antibody NK cell therapy Modified by Santoni M, AIOM 2014
44 New Combinations trials in mrcc Abstract #4509: Pegilodecakin with nivolumab (nivo) or pembrolizumab (pembro) in patients (pts) with metastatic renal cell carcinoma (RCC). Abstract #4510: A phase 1/2 study evaluating the efficacy and safety of the oral CXCR4 inhibitor X4P-001 in combination with axitinib in patients with advanced renal cell carcinoma. Tannir NM et al., J Clin Oncol 36, 2018 (suppl; abstr 4509) Vaishampayan UN et al., J Clin Oncol 36, 2018 (suppl; abstr 4510)
45 New Combinations trials in mrcc Abstract #4509: Pegilodecakin with nivolumab (nivo) or pembrolizumab (pembro) in patients (pts) with metastatic renal cell carcinoma (RCC). Abstract #4510: A phase 1/2 study evaluating the efficacy and safety of the oral CXCR4 inhibitor X4P-001 in combination with axitinib in patients with advanced renal cell carcinoma. Tannir NM et al., J Clin Oncol 36, 2018 (suppl; abstr 4509) Vaishampayan UN et al., J Clin Oncol 36, 2018 (suppl; abstr 4510)
46 Pegilodecakin (AM0010) Mechanism of Action Pegilodecakin (AM0010) ia a pegylated recombinant human IL-10 Interleukin-10 (IL-10) stimulates the expansion and cytotoxicity of tumorinfiltrating CD8+ T cells and inhibits inflammatory CD4+ T cells Rationale for Pegilodecakin + anti-pd-1 Anti-PD-1 increases TCR signal Pegilodecakin prevents exhaustion and apoptosis Pegilodecakin induces CD8+ T cell activation Tannir NM et al., J Clin Oncol 36, 2018 (suppl; abstr 4509)
47 Pegilodecakin + anti-pd-1 in RCC Patients population Anti-PD-1 naive Tannir NM et al., J Clin Oncol 36, 2018 (suppl; abstr 4509)
48 Pegilodecakin + anti-pd-1 in RCC Safety The selected MTD/ph2 for AM0010 is 10 µg/kg in combination with anti-pd-1 Tannir NM et al., J Clin Oncol 36, 2018 (suppl; abstr 4509)
49 Pegilodecakin + anti-pd-1 in RCC Activity Modified by Laurence Albiges, ASCO 2018 Tannir NM et al., J Clin Oncol 36, 2018 (suppl; abstr 4509)
50 Pegilodecakin Biomarker analysis Modified by Laurence Albiges, ASCO 2018 Pegilodecakin + Anti-PD-1 induces clonal T cell expansion in the blood of RCC patients Tannir NM et al., J Clin Oncol 36, 2018 (suppl; abstr 4509)
51 Pegilodecakin + anti-pd-1 in RCC Open questions Shall we move this combination further? YES Where to fit in the treatment landscape? Are the data strong enough in first line? Probably not against nivo-ipi or VEGF TKI-IO combination How would Pg IL-10- PD-1i combination work in immune checkpoint inhibitor combination pretreated patients?
52 New Combinations trials in mrcc Abstract #4509: Pegilodecakin with nivolumab (nivo) or pembrolizumab (pembro) in patients (pts) with metastatic renal cell carcinoma (RCC). Abstract #4510: A phase 1/2 study evaluating the efficacy and safety of the oral CXCR4 inhibitor X4P-001 in combination with axitinib in patients with advanced renal cell carcinoma. Tannir NM et al., J Clin Oncol 36, 2018 (suppl; abstr 4509) Vaishampayan UN et al., J Clin Oncol 36, 2018 (suppl; abstr 4510)
53 Renal Cell Carcinoma and CXCR4 The CXCR4 chemokine receptor is expressed in many tumors, including clear cell RCC, where it promotes angiogenesis and enhances tumor infiltration by myeloidderived suppressor cells (MDSCs) and T regulatory cells (Tregs) Elevated expression of CXCR4 by RCC tumors is correlated with poor prognosis X4P-001 is an orally available, selective, CXCR4 antagonist that allosterically inhibits receptor binding by CXCL12 Burger e Kipps, Blood 2006; 107,1761
54 X4P Axitinib Phase 1-2, multi-center, open label study of X4P-001 in combination with axitinib in patients with clear cell RCC who have received at least 1 prior systemic therapy Safety analysis included 65 patients from phase 1-2 that were treated with 400 mg X4P-001 (200 mg BID or 400 mg QD) + 3 mg BID axitinib Treatment response were assessed using RECIST v1.1 every 8 weeks by blinded, indipendent central review Vaishampayan UN et al., J Clin Oncol 36, 2018 (suppl; abstr 4510)
55 X4P Axitinib Patient population Vaishampayan UN et al., J Clin Oncol 36, 2018 (suppl; abstr 4510)
56 X4P Axitinib Safety 8 patients discontinued treatment due treatment-related Aes Hypertension Creatinine increase Diarrhea Fatigue Hyperkalemia Retinal vein occlusion Sepsis Vaishampayan UN et al., J Clin Oncol 36, 2018 (suppl; abstr 4510)
57 X4P Axitinib Preliminary activity Vaishampayan UN et al., J Clin Oncol 36, 2018 (suppl; abstr 4510)
58 X4P Axitinib Open questions Shall we move this combination further? NO based on current data Was VEGFR TKI the right backbone for the agent? Could PD-1i+CXCR4i be more relevant? NCT (nivolumab+x4p- 001)
59
Francesco Massari Oncologia Medica Azienda Ospedaliero Universitaria di Bologna Policlinico S. Orsola-Malpighi
Focus sulla malattia metastatica ormonosensibile (mhspc) ADT e Chemioterapia: quando e a chi? Francesco Massari Oncologia Medica Azienda Ospedaliero Universitaria di Bologna Policlinico S. Orsola-Malpighi
More informationFrancesco Massari Oncologia Medica Azienda Ospedaliero Universitaria di Bologna Policlinico S. Orsola-Malpighi
Prostata: Oral Communications Emerging strategies and controversial topics in advanced prostate cancer Francesco Massari Oncologia Medica Azienda Ospedaliero Universitaria di Bologna Policlinico S. Orsola-Malpighi
More informationDevelopping the next generation of studies in RCC
Developping the next generation of studies in RCC Bernard Escudier Institut Gustave Roussy Villejuif, France Disclosure Information Advisory/Consultancy Role Pfizer, Exelixis, Novartis, BMS, Bayer, Roche,
More informationProstate cancer Management of metastatic castration sensitive cancer
18 th Annual Advances in Oncology - 2017 Prostate cancer Management of metastatic castration sensitive cancer Urothelial carcinoma Non-muscle invasive urothelial carcinoma Updates in metastatic urothelial
More informationRevisione Oral Abstracts
Revisione Oral Abstracts Francesco Massari Oncologia Medica Azienda Ospedaliero Universitaria di Bologna Policlinico S. Orsola-Malpighi UPDATES and NEWS from the Genitourinary Cancers Symposium - Milano,
More informationSergio Bracarda MD, Head, Department of Oncology Azienda USL Toscana Sud-Est Istituto Toscano Tumori (ITT) Ospedale San Donato Arezzo, Italy
Sergio Bracarda MD, Head, Department of Oncology Azienda USL Toscana Sud-Est Istituto Toscano Tumori (ITT) Ospedale San Donato Arezzo, Italy Milano, 3 marzo 2017 Prostata: Castration resistant HIGHLIGHTS
More informationLa revolución de la inmunoterapia: dónde la posicionamos? Javier Puente, MD, PhD
La revolución de la inmunoterapia: dónde la posicionamos? Javier Puente, MD, PhD Hospital Universitario Clinico San Carlos Medical Oncology Department Thoracic & Urological Cancer Unit Complutense University
More informationDevelopmental Therapeutics for Genitourinary Malignancies
Developmental Therapeutics for Genitourinary Malignancies Russell Szmulewitz, MD April 2018 Disclosure Information 23 rd Annual Developmental Therapeutics Symposium Name of Speaker I have the following
More informationCheckpoint regulators a new class of cancer immunotherapeutics. Dr Oliver Klein Medical Oncologist ONJCC Austin Health
Checkpoint regulators a new class of cancer immunotherapeutics Dr Oliver Klein Medical Oncologist ONJCC Austin Health Cancer...Immunology matters Anti-tumour immune response The participants Dendritc cells
More informationImmunotherapy for the Treatment of Melanoma. Marlana Orloff, MD Thomas Jefferson University Hospital
Immunotherapy for the Treatment of Melanoma Marlana Orloff, MD Thomas Jefferson University Hospital Disclosures Immunocore and Castle Biosciences, Consulting Fees I will be discussing non-fda approved
More informationII sessione. Immunoterapia oltre la prima linea. Alessandro Tuzi ASST Sette Laghi, Varese
II sessione Immunoterapia oltre la prima linea Alessandro Tuzi ASST Sette Laghi, Varese AGENDA Immunotherapy post-chemo ( true 2/3L ) Immunotherapy in oncogene addicted NSCLC (yes/no? when?) Immunotherapy
More informationMELANOMA METASTASICO: NUEVAS COMBINACIONES. Dr Ana Arance MD PhD Oncología Médica Hospital Clínic Barcelona
MELANOMA METASTASICO: NUEVAS COMBINACIONES Dr Ana Arance MD PhD Oncología Médica Hospital Clínic Barcelona Summary of OS accross clinical trials in patients with metastatic melanoma Ugurel et al. Eur J
More informationChallenging Genitourinary Tumors: What s New in 2017
Challenging Genitourinary Tumors: What s New in 2017 David J. Vaughn, MD Genitourinary Medical Oncology Professor Please note that some of the studies reported in this presentation were presented as an
More informationCurrent experience in immunotherapy for metastatic renal cell carcinoma
Current experience in immunotherapy for metastatic renal cell carcinoma Axel Bex, MD, PhD The Netherlands Cancer Institute FOIU, Tel Aviv, 3 July 2018 Financial and Other Disclosures Off-label use of drugs,
More informationASCO 2012 Genitourinary tumors
ASCO 2012 Genitourinary tumors Post ASCO Bern 14-06-2012 Dr. med. Richard Cathomas leitender Arzt Onkologie, KSGR, Chur Renal cell cancer Changes in first line treatment? Prostate cancer 3 positive phase
More informationImmunotherapy, an exciting era!!
Immunotherapy, an exciting era!! Yousef Zakharia MD University of Iowa and Holden Comprehensive Cancer Center Alliance Meeting, Chicago November 2016 Presentation Objectives l General approach to immunotherapy
More informationMelanoma. Il parere dell esperto. V. Ferraresi. Divisione di Oncologia Medica 1
Melanoma Il parere dell esperto V. Ferraresi Divisione di Oncologia Medica 1 MELANOMA and ESMO 2017.what happens? New data and updates ADJUVANT THERAPY with CHECKPOINT INHIBITORS (CA209-238 trial) AND
More informationNew Avenues for the development and evaluation of therapy: Complex, multi-pronged, not one size fitting all
New Avenues for the development and evaluation of therapy: Complex, multi-pronged, not one size fitting all Antoine Yver MD MSC Senior VP & Head Oncology Global Medicines Development AstraZeneca, Gaithersburg
More informationImmunotherapy versus targeted treatments in metastatic renal cell carcinoma: The return game?
Immunotherapy versus targeted treatments in metastatic renal cell carcinoma: The return game? Sylvie NEGRIER MD, PhD Centre Léon Bérard, Lyon Université Lyon I IMMUNOTHERAPY: A LONG AND WIDING ROAD! WHERE
More informationPerspective on endocrine and chemotherapy agents. Cora N. Sternberg Department of Medical Oncology San Camillo & Forlanini Hospitals Rome, Italy
Perspective on endocrine and chemotherapy agents Cora N. Sternberg Department of Medical Oncology San Camillo & Forlanini Hospitals Rome, Italy Disclosures Dr. Sternberg has received research funding for
More informationSESSIONE PLATINUM SERIES (Best Papers Poster o Abstract on Prostate Cancer) In Oncologia
SESSIONE PLATINUM SERIES (Best Papers Poster o Abstract on Prostate Cancer) In Oncologia Divisione di Oncologia Medica Unità Tumori Genitourinari SESSIONE PLATINUM SERIES (Best Papers Poster o Abstract
More informationWhat will change for men with advanced prostate cancer in the next 24 months? ESO Observatory: Perspective on endocrine and chemotherapy agents
Perspective on endocrine and chemotherapy agents Cora N. Sternberg Department of Medical Oncology San Camillo & Forlanini Hospitals Rome, Italy Disclosures Dr.Sternberg has received research funding for
More informationASCO 2011 Genitourinary Cancer
ASCO 2011 Genitourinary Cancer Expanding Options for Chronic Diseases? Walter Stadler, MD, FACP University of Chicago Disclosures (All Non-University &/or Financial Dealings with Potential, Real, or Perceived
More informationCheckpoint Regulators Cancer Immunotherapy takes centre stage. Dr Oliver Klein Department of Medical Oncology 02 May 2015
Checkpoint Regulators Cancer Immunotherapy takes centre stage Dr Oliver Klein Department of Medical Oncology 02 May 2015 Adjuvant chemotherapy improves outcome in early breast cancer FDA approval of Imatinib
More informationIndication for- and timing of cytoreductive nephrectomy Kidney- and bladder cancer: Immunotherapy
Indication for- and timing of cytoreductive nephrectomy Kidney- and bladder cancer: Immunotherapy Axel Bex, MD, PhD The Netherlands Cancer Institute Oslo, September 4, 2018 Financial and Other Disclosures
More informationBrain mets under I.O.
Brain mets under I.O. Bernard Escudier Gustave Roussy, Villejuif, France Disclosure Honorarium received from BMS, Novartis, Pfizer, Bayer, Roche, Exelixis, Ipsen, Eisai, Calithera Travel Grant from BMS,
More informationIMMUNOTHERAPY FOR GASTROINTESTINAL CANCERS
IMMUNOTHERAPY FOR GASTROINTESTINAL CANCERS Dr Elizabeth Smyth Cambridge University Hospitals NHS Foundation Trust ESMO Gastric Cancer Preceptorship Valencia 2018 DISCLOSURES Honoraria for advisory role
More informationNuove opzioni terapeutiche nel Carcinoma della Prostata: IMMUNOTERAPIA. Andrea Sbrana U.O. Oncologia Medica 2 Universitaria AOU Pisana
Nuove opzioni terapeutiche nel Carcinoma della Prostata: IMMUNOTERAPIA Andrea Sbrana U.O. Oncologia Medica 2 Universitaria AOU Pisana Until now: Some success Kantoff et al, N Engl J Med 2010 Kantoff et
More informationImmunotherapy for Genitourinary Cancers
Immunotherapy for Genitourinary Cancers Susan F. Slovin, MD, PhD Genitourinary Oncology Service Sidney Kimmel Center for Prostate and Urologic Cancers Memorial Sloan Kettering Cancer Center New York, New
More informationImmunotherapy for the Treatment of Cancer
Immunotherapy for the Treatment of Cancer Jason Muhitch, PhD Assistant Professor Department of Urology Department of Immunology Roswell Park Comprehensive Cancer Center Oncology for Scientists March 15,
More informationPROSTATE CANCER HORMONE THERAPY AND BEYOND. Przemyslaw Twardowski MD Professor of Oncology Department of Urologic Oncology John Wayne Cancer Institute
PROSTATE CANCER HORMONE THERAPY AND BEYOND Przemyslaw Twardowski MD Professor of Oncology Department of Urologic Oncology John Wayne Cancer Institute Disclosures I am a Consultant for Bayer and Sanofi-Aventis
More informationHormone sensitive prostate cancer To add abiraterone or docetaxel? Dr Lisa Pickering
> Hormone sensitive prostate cancer To add abiraterone or docetaxel? Dr Lisa Pickering Disclosures Institutional Research Support/P.I. Employee Consultant Major Stockholder Speakers Bureau Honoraria Scientific
More informationNivolumab: esperienze italiane nel carcinoma polmonare avanzato
NSCLC avanzato: quali novità nel 2018? Negrar, 30 Ottobre 2018 Nivolumab: esperienze italiane nel carcinoma polmonare avanzato Francesco Grossi UOC Oncologia Medica Fondazione IRCCS Ca Granda Ospedale
More informationESMO SUMMIT MIDDLE EAST 2018
ESMO SUMMIT MIDDLE EAST 2018 14 Years of progress in Prostate Cancer Standards of Care and new targets Name Ronald de Wit 6-7 April 2018, Dubai, UAE CONFLICT OF INTEREST DISCLOSURE Sub-title Sanofi Roche
More informationO DESAFIO DA INOVAÇÃO EM ONCOLOGIA EM PORTUGAL The Challenges of innovative oncology care in Portugal. Gabriela Sousa Oncologia Médica IPO Coimbra
O DESAFIO DA INOVAÇÃO EM ONCOLOGIA EM PORTUGAL The Challenges of innovative oncology care in Portugal Gabriela Sousa Oncologia Médica IPO Coimbra Incidência aumenta 3% ao ano Envelhecimento populacional
More informationTHE SEARCH FOR BIOMARKERS IN BLADDER CANCER
THE SEARCH FOR BIOMARKERS IN BLADDER CANCER CDDP and IO WORLD ALEJO RODRÍGUEZ-VIDA MD PhD Consultant Medical Oncologist Associate Professor Hospital del Mar, Barcelona November 23 rd 2018 DISCLOSURE OF
More informationRenal Cell Carcinoma: Systemic Therapy Progress and Promise
Renal Cell Carcinoma: Systemic Therapy Progress and Promise Michael B. Atkins, M.D. Deputy Director, Lombardi Comprehensive Cancer Ctr Georgetown University Medical Center Everolimus Rini, Campbell, Escudier.
More information2014 Treatment Paradigms in mcrpc Docetaxel in hormone sensitive PC
Ronald de Wit Erasmus MC Cancer Institute The Netherlands 2014 Treatment Paradigms in mcrpc Docetaxel in hormone sensitive PC Disclosures Sanofi ; research grant support, consultancy and speaker fees Astellas;
More informationImmunotherapy for the Treatment of Kidney and Bladder Cancer
Immunotherapy for the Treatment of Kidney and Bladder Cancer Alan J. Koletsky, MD Genitourinary Cancer Research Program, Lynn Cancer Institute Clinical Asistant Professor of Biomedical Science The Charles
More informationOngoing trials that might change the standard of care in mcrpc
Ongoing trials that might change the standard of care in mcrpc Igor Tsaur University Medicine Mainz COI Off-label use of drugs, devices, or other agents: none Data from IRB-approved human research is presented:
More informationCLINICAL CHALLENGES IN METASTATIC RENAL CELL CARCINOMA: THE RIGHT THERAPY FOR THE RIGHT PATIENT
Daniel Heng, MD, MPH, FRCPC @DrDanielHeng Chair GU Tumour Group, Tom Baker Cancer Centre Clinical Professor, University of Calgary CLINICAL CHALLENGES IN METASTATIC RENAL CELL CARCINOMA: THE RIGHT THERAPY
More informationCheckpointinhibitoren in der Uro-Onkologie. Carsten Grüllich
Checkpointinhibitoren in der Uro-Onkologie Carsten Grüllich 07.02.15 T-cell Aktivierung und Regulation T cell Costimulation Recognition MHC I Peptide b2m mrna Tumorantigen Tumor Pardoll Nature Rev Cancer
More informationWhat we learned from immunotherapy in the past years
What we learned from immunotherapy in the past years Paolo A. Ascierto, MD Unit Melanoma, Cancer Immunotherapy and Innovative Therapies Istituto Nazionale Tumori Fondazione G. Pascale, Napoli, Italy Disclosure
More informationFifteenth International Kidney Cancer Symposium November 4-5, 2016 Marriott Miami Biscayne Bay, Miami, Florida, USA
The following presentation should not be regarded as an endorsement of a particular product/drug/technique by the speaker. The presentation topics were assigned to the speakers by the scientific committee
More informationCarcinoma renale metastatico: cambia la pratica clinica? Camillo Porta Fondazione I.R.C.C.S. Policlinico San Matteo, Pavia
Carcinoma renale metastatico: cambia la pratica clinica? Camillo Porta Fondazione I.R.C.C.S. Policlinico San Matteo, Pavia New target, new agent (James Brugarolas) Atezolizumab + Bevacizumab and PD-L1
More informationPTAC meeting held on 5 & 6 May (minutes for web publishing)
PTAC meeting held on 5 & 6 May 2016 (minutes for web publishing) PTAC minutes are published in accordance with the Terms of Reference for the Pharmacology and Therapeutics Advisory Committee (PTAC) and
More informationWeitere Kombinationspartner der Immunotherapie
1 Weitere Kombinationspartner der Immunotherapie Rolf Stahel University Hospital of Zürich Zürich, 9.12.216 2 Immunotherapy in a multimodality approach NSCLC Advanced disease Checkpoint inhibitors for
More informationNegative Trials in RCC: Where Did We Go Wrong? Can We Do Better?
Negative Trials in RCC: Where Did We Go Wrong? Can We Do Better? 9 th European Kidney Cancer Symposium, Dublin, April 2014 Tim Eisen Tim Eisen - Disclosures Company Research Support Advisory Board Trial
More informationSecond line hormone therapies. Dr Lisa Pickering Consultant Medical Oncologist ESMO Preceptorship Singapore 2017
Second line hormone therapies Dr Lisa Pickering Consultant Medical Oncologist ESMO Preceptorship Singapore 2017 Disclosures Institutional Research Support/P.I. Employee Consultant Major Stockholder Speakers
More informationImmunotherapy for Renal Cell Carcinoma. James Larkin
Immunotherapy for Renal Cell Carcinoma James Larkin Disclosures Institutional research support: BMS, MSD, Novartis, Pfizer Consultancy (all non-remunerated): Eisai, BMS, MSD, GSK, Pfizer, Novartis, Roche/Genentech
More informationCarcinoma renale. Francesco Atzori. Oncologia Medica Azienda Ospedaliero Universitaria Cagliari. Posters & Oral abstracts
Carcinoma renale Posters & Oral abstracts Francesco Atzori Oncologia Medica Azienda Ospedaliero Universitaria Cagliari Milano 3 marzo 2017 Renal Cell Cancer Track 2017 Genitourinary Cancers Symposium Poster
More informationImmunotherapies for Advanced NSCLC: Current State of the Field. H. Jack West Swedish Cancer Institute Seattle, Washington
Immunotherapies for Advanced NSCLC: Current State of the Field H. Jack West Swedish Cancer Institute Seattle, Washington Nivolumab in Squamous NSCLC Chemo-pretreated (1 st line) Adv squamous NSCLC N =
More informationColorectal Cancer in 2017: From Biology to the Clinics. Rodrigo Dienstmann
Colorectal Cancer in 2017: From Biology to the Clinics Rodrigo Dienstmann MOLECULAR CLASSIFICATION Tumor cell Immune cell Tumor microenvironment Stromal cell MOLECULAR CLASSIFICATION Biomarker Tumor cell
More informationSequencing Strategies in Metastatic Castration Resistant Prostate Cancer (MCRPC)
Sequencing Strategies in Metastatic Castration Resistant Prostate Cancer (MCRPC) Amit Bahl Consultant Oncologist Bristol Cancer Institute Clinical Director Spire Specialist Care Centre UK Disclosures Advisory
More informationInnovaciones en el tratamiento del ca ncer renal. Enrique Grande
Innovaciones en el tratamiento del ca ncer renal Enrique Grande The enriched inflammatory environment of RCC Chen Z, et al. Nat Rev Cancer 2014 Available agents are expanding across the three eras of arcc
More informationEmerging Biomarkers of VEGF and mtor Inhibitors in 2015
Emerging Biomarkers of VEGF and mtor Inhibitors in 2015 Laurence Albiges Institut Gustave Roussy, France Fourteenth International Kidney Cancer Symposium Miami, Florida, USA November 6-7, 2015 www.kidneycancersymposium.com
More informationClinical Biomarker in Kidney Cancer. Maria Nirvana Formiga, M.D., Ph.D.
Clinical Biomarker in Kidney Cancer Maria Nirvana Formiga, M.D., Ph.D. Disclosures I am on the Speaker s Bureau with Pfizer and Bayer Clinical trials of BMS and Pfizer Kidney Cancer 70% new cases in developed
More informationGenomics and Genetics in BC: Precise selection for chemotherapy and Immunotherapy. Raanan Berger MD PhD Sheba Medical Center, Israel
Genomics and Genetics in BC: Precise selection for chemotherapy and Immunotherapy Raanan Berger MD PhD Sheba Medical Center, Israel Disclosures Honoraria, Ad board BMS, MSD, Pfizer, Astra Zeneca, Bayer,
More informationSquamous Cell Carcinoma Standard and Novel Targets.
Squamous Cell Carcinoma Standard and Novel Targets. Mohamed K. Mohamed, MD, PhD Director of Thoracic Oncology Cone Health Cancer Center Greensboro, NC 1 Mohamed Mohamed, MD, PhD Squamous Cell Carcinoma:
More informationRenal Cell Carcinoma: Navigating a Maze of Choices
Renal Cell Carcinoma: Navigating a Maze of Choices Sumanta Kumar Pal, M.D. Associate Professor Department of Medical Oncology & Experimental Therapeutics Co-Director, Kidney Cancer Program City of Hope
More information2019 ASCO-SITC. Nektar Therapeutics Investor & Analyst Call. March 1, 2019
Nektar Therapeutics Investor & Analyst Call March 1, 2019 This presentation includes forward-looking statements regarding Nektar s proprietary drug candidates, the timing of the start and conclusion of
More informationNEXT GENERATION DRUGS IN KIDNEY CANCER. Dr Aine O Reilly Karolinska Institutet Stockholm, Sweden
NEXT GENERATION DRUGS IN KIDNEY CANCER Dr Aine O Reilly Karolinska Institutet Stockholm, Sweden KIDNEY CANCER SUBTYPES Papillary Type 1 and 2 Medullary Collecting duct Chromophobe Translocation Clear cell
More informationInmunoterapia en cáncer renal metastásico: redefiniendo el tratamiento de segunda línea
Inmunoterapia en cáncer renal metastásico: redefiniendo el tratamiento de segunda línea Daniel Castellano Oncología Médica. Unidad de Tumores Genito-Urinarios Hospital Universitario 12 de Octubre I + 12
More informationOut of 129 patients with NSCLC treated with Nivolumab in a phase I trial, the OS rate at 5-y was about 16 %, clearly higher than historical rates.
6th Meeting on external quality assessment in molecular pathology, Naples, May 12-13, 2017 Overview of clinical development of checkpoint inhibitors in solid tumors Pr Jaafar BENNOUNA University of Nantes
More informationBiomarkers in Imunotherapy: RNA Signatures as predictive biomarker
Biomarkers in Imunotherapy: RNA Signatures as predictive biomarker Joan Carles, MD PhD Director GU, CNS and Sarcoma Program Department of Medical Oncology Vall d'hebron University Hospital Outline Introduction
More informationHighlights STOMACH CANCER
UPDATES and NEWS from the Gastrointestinal Cancers Symposium in San Francisco Roma, 10-11 Febbraio 2017 Highlights STOMACH CANCER Lorenzo Fornaro, MD Unit of Medical Oncology 2 Azienda Ospedaliero-Universitaria
More informationImmunotherapy for NSCLC: Current State of the Art and Future Directions. H. Jack West, MD Swedish Cancer Institute Seattle, Washington, United States
Immunotherapy for NSCLC: Current State of the Art and Future Directions H. Jack West, MD Swedish Cancer Institute Seattle, Washington, United States Which of the following statements regarding immunotherapy
More informationTumori Genito-Urinari. Fabio Calabrò Oncologia Medica Azienda Ospedaliera San Camillo Forlanini
Tumori Genito-Urinari Fabio Calabrò Oncologia Medica Azienda Ospedaliera San Camillo Forlanini Prostate cancer treatment paradigm is evolving PROSTATE CANCER TREATMENT PARADIGMIS EVOLVING Non metatasticcrpc
More informationpan-canadian Oncology Drug Review Stakeholder Feedback on a pcodr Request for Advice Axitinib (Inlyta) for Metastatic Renal Cell Carcinoma
pan-canadian Oncology Drug Review Stakeholder Feedback on a pcodr Request for Advice Axitinib (Inlyta) for Metastatic Renal Cell Carcinoma Pfizer Canada Inc. June 29, 2017 3 Stakeholder Feedback on a pcodr
More informationPresenter Disclosure Information
Presenter Disclosure Information Tara C. Gangadhar, M.D. The following relationships exist related to this presentation: Research funding (Institution): Incyte Corporation and Merck & Co., Inc Preliminary
More informationMariano Provencio Servicio de Oncología Médica Hospital Universitario Puerta de Hierro. Immune checkpoint inhibition in DLBCL
Mariano Provencio Servicio de Oncología Médica Hospital Universitario Puerta de Hierro Immune checkpoint inhibition in DLBCL Immunotherapy: The Cure is Inside Us Our immune system prevents or limit infections
More informationNSCLC: immunotherapy as a first-line treatment. Paolo Bironzo Oncologia Polmonare AOU S. Luigi Gonzaga Orbassano (To)
NSCLC: immunotherapy as a first-line treatment Paolo Bironzo Oncologia Polmonare AOU S. Luigi Gonzaga Orbassano (To) The 800-pound gorilla Platinum-based chemotherapy is the SOC for 1st-line therapy in
More informationLung Cancer Immunotherapy
Lung Cancer Immunotherapy Luis E. Raez MD FACP FCCP Chief of Hematology/Oncology & Medical Director Memorial Cancer Institute/Memorial Health Care System Clinical Professor of Medicine Herbert Wertheim
More informationImmune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment
Immune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment 1 Introductions Peter Langecker, MD, PhD Executive Medical Director, Global Oncology Clinipace Worldwide Mark Shapiro Vice President
More informationESMO Madrid, Spain Associate Professor Brian Costello Division of Medical Oncology, Genitourinary Tumour Group, Mayo Clinic, USA
ESMO 2017 - Madrid, Spain Associate Professor Brian Costello Division of Medical Oncology, Genitourinary Tumour Group, Mayo Clinic, USA HIGHLIGHTS ON RENAL CELL CARCINOMA CHECKMATE 214: EFFICACY AND SAFETY
More informationManagement of Incurable Prostate Cancer in 2014
Management of Incurable Prostate Cancer in 2014 Julie N. Graff, MD, MCR Portland VA Medical Center Assistant Professor of Medicine Knight Cancer Institute, OHSU 2014: Cancer Estimates Stage at Diagnosis
More informationNewLink Genetics Corporation
Cantor Fitzgerald Global Healthcare Conference NewLink Genetics Corporation NASDAQ: NLNK September 25, 2017 Forward-Looking Disclaimer This presentation contains forward-looking statements of NewLink that
More informationJefferies 2018 Healthcare Conference. June 6, 2018
Jefferies 2018 Healthcare Conference z June 6, 2018 This presentation includes forward-looking statements regarding Nektar s proprietary drug candidates, the timing of the start and conclusion of ongoing
More informationDisclosures. Immunotherapyin Head & NeckCancer. Actual landscape of systemic treatment in HNSCC. Head andneckcanceris an immunogeneic tumor
Immunotherapyin Head & NeckCancer Disclosures Astra-Zeneca/medimmune: clinical trial BMS: advisory board, clinical trial Merck: advisory board, clinical trial, research funding Carla van Herpen Medical
More informationNew Systemic Therapies in Advanced Melanoma
New Systemic Therapies in Advanced Melanoma Sanjay Rao, MD FRCPC Medical Oncologist (BCCA-CSI) Clinical Assistant Professor, UBC Faculty of Medicine SON Fall Update October 22, 2016 Disclosures Equity
More informationImmune Checkpoint Inhibitors for Lung Cancer William N. William Jr.
Immune Checkpoint Inhibitors for Lung Cancer William N. William Jr. Diretor de Onco-Hematologia Hospital BP, A Beneficência Portuguesa Non-Small Cell Lung Cancer PD-1/PD-L1 Inhibitors in second-line therapy
More informationLiver and Biliary Tract Cancers Critical Review
Liver and Biliary Tract Cancers Critical Review Lorenza Rimassa Oncologia Medica e Ematologia Humanitas Cancer Center Humanitas Research Hospital Rozzano (Milano) Critical review Oral presentations Melero
More informationMetastatic NSCLC: Expanding Role of Immunotherapy. Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian
Metastatic NSCLC: Expanding Role of Immunotherapy Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian Disclosures: No relevant disclosures Please note that some of the studies reported in
More informationOverview: Immunotherapy in CNS Metastases
Overview: Immunotherapy in CNS Metastases Manmeet Ahluwalia, MD, FACP Miller Family Endowed Chair in Neuro-Oncology Director Brain Metastasis Research Program Cleveland Clinic Disclosures Consultant- Monteris
More informationTargeted and immunotherapy in RCC
Targeted and immunotherapy in RCC Treatment options Surgery (radical VS partial nephrectomy) Thermal ablation therapy Surveillance Immunotherapy Molecular targeted therapy Molecular targeted therapy Targeted
More informationRenal Cell Cancer: Present and Future. Bernard Escudier, Gustave Roussy
Renal Cell Cancer: Present and Future Bernard Escudier, Gustave Roussy [HKIOF May 2017] Sponsored by Bristol- Myers Squibb OPDIVO Hong Kong prescribing information is available upon request Disclosures
More informationSecond - Line Debate: Axitinib
Second - Line Debate: Axitinib Alain Ravaud, MD PhD Bordeaux, France DISCLOSURES Member of Global, European and/or French advisory board in RCC and/or GU tumors for Pfizer, Novartis, GSK, Roche, BMS, Merck.
More informationCheckMate 012: Safety and Efficacy of First Line Nivolumab and Ipilimumab in Advanced Non-Small Cell Lung Cancer
CheckMate 12: Safety and Efficacy of First Line Nivolumab and Ipilimumab in Advanced Non-Small Cell Lung Cancer Abstract 31 Hellmann MD, Gettinger SN, Goldman J, Brahmer J, Borghaei H, Chow LQ, Ready NE,
More informationProspettive future nel trattamento medico del mrcc. Francesco Massari Oncologia Medica Policlinico S Orsola-Malpighi Bologna
Prospettive future nel trattamento medico del mrcc Francesco Massari Oncologia Medica Policlinico S Orsola-Malpighi Bologna 3 rd YOUNG SPECIALIST RENAL CARE Firenze, 09 Aprile 2016 Renal cell carcinoma
More informationDavid N. Robinson, MD
David N. Robinson, MD Background and Treatment of mrcc Background ~ 64,770 new cases of kidney/renal pelvis cancers will be diagnosed in the US in 2012 with an estimated 13,570 deaths [1] ~ 75% are clear-cell
More informationNOVITA IN TEMA DI CARCINOMA GASTRICO ROSA BERENATO
NOVITA IN TEMA DI CARCINOMA GASTRICO ROSA BERENATO ONCOLOGIA MEDICA 1 FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI MILANO PROGRESS AGAINST METASTATIC GC OS in first-line palliative setting Little progress
More informationmcrpc 2014 TRA EVOLUZIONE E RIVOLUZIONE: COME ORIENTARSI NEL LABIRINTO DELLE TERAPIE
mcrpc 2014 TRA EVOLUZIONE E RIVOLUZIONE: COME ORIENTARSI NEL LABIRINTO DELLE TERAPIE IL CARCINOMA PROSTATICO, UNA MALATTIA ETEROGENEA? RAZIONALE E RISULTATI DEL TRATTAMENTO CHEMIOTERAPICO ASSOCIATO ALL
More informationLONDON CANCER NEW DRUGS GROUP RAPID REVIEW
LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Abiraterone for the treatment of metastatic castration-resistant prostate cancer that has progressed on or after a docetaxel-based chemotherapy regimen Disease
More informationNivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mrcc): Results of a phase I trial
Nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mrcc): Results of a phase I trial H. Hammers, E.R. Plimack, J.R. Infante, M.S. Ernstoff, B. Rini, D.F. McDermott, A. Razak,
More informationImmune Checkpoint Therapy Toxicities: Lessons learned and new strategies to improve outcomes
Immune Checkpoint Therapy Toxicities: Lessons learned and new strategies to improve outcomes Geoffrey T. Gibney, MD Associate Professor Co-leader, Melanoma Disease Group Lombardi Comprehensive Cancer Center
More informationMelanoma: Immune checkpoints
ESMO Preceptorship Programme Immuno-Oncology Siena, July 04-05, 2016 Melanoma: Immune checkpoints Michele Maio Medical Oncology and Immunotherapy-Department of Oncology University Hospital of Siena, Istituto
More informationImmuno-Oncology Applications
Immuno-Oncology Applications Lee S. Schwartzberg, MD, FACP West Clinic, P.C.; The University of Tennessee Memphis, Tn. ICLIO 1 st Annual National Conference 10.2.15 Philadelphia, Pa. Financial Disclosures
More informationONCOS-102 in melanoma Dr. Alexander Shoushtari. 4. ONCOS-102 in mesothelioma 5. Summary & closing
ONCOS-102 in melanoma Dr. Alexander Shoushtari 4. ONCOS-102 in mesothelioma 5. Summary & closing 1 Preliminary data from C824 Activating the Alexander Shoushtari, MD Assistant Attending Physician Melanoma
More informationImmunotherapy in Unresectable or Metastatic Melanoma: Where Do We Stand? Sanjiv S. Agarwala, MD St. Luke s Cancer Center Bethlehem, Pennsylvania
Immunotherapy in Unresectable or Metastatic Melanoma: Where Do We Stand? Sanjiv S. Agarwala, MD St. Luke s Cancer Center Bethlehem, Pennsylvania Overview Background Immunotherapy clinical decision questions
More informationThe Immunotherapy of Oncology
The Immunotherapy of Oncology The 30-year Overnight Success Story M Avery, BIOtech Now 2014 Disclosures: Geoffrey R. Weiss, M.D. None The History A. Chekov: It has long been noted that the growth of malignant
More information